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Abstract
Introduction: Autoantibodies directed against citrullinated proteins/peptides (ACPAs) are highly specific and
predictive for the development of rheumatoid arthritis (RA). Different subgroups of RA patients, which have
different prognoses and may require different treatments, are characterized by different autoantibody profiles.
The objective of this study was to develop a microarray for the detection of multiple RA-associated autoantibodies,
initially focusing on responses against citrullinated epitopes on candidate autoantigens in RA.
Methods: The microarray is based on Phadia’s ImmunoCAP ISAC system, with which reactivity to more than 100
antigens can be analyzed simultaneously, by using minute serum volumes (< 10 μl). Twelve citrullinated peptides,
and the corresponding native arginine-containing control peptides, were immobilized in an arrayed fashion onto a
chemically modified glass slide, allowing a three-dimensional layer with high binding capacity. The assay was
optimized concerning serum dilution and glass surface, whereas each individual antigen was optimized concerning
coupling chemistry, antigen concentration, and selection of spotting buffer. The performance of each peptide in
the ImmunoCAP ISAC system was compared with the performance in enzyme-linked immunosorbent assays
(ELISAs). Serum from 927 RA patients and 461 healthy controls from a matched case-control study were applied
onto reaction sites on glass slides, followed by fluorescent-labeled anti-human immunoglobulin G (IgG) antibody.
Fluorescence intensities were detected with a laser scanner, and the results analyzed by using image-analysis
software.
Results: Strong correlations between the ImmunoCAP ISAC system and ELISA results were found for individual
citrullinated peptides (Spearman r typically between 0.75 and 0.90). Reactivity of RA sera with the peptides was
seen mainly in the anticyclic citrullinated peptide 2 (CCP2)-positive subset, but some additional reactivity with
single citrullinated peptides was seen in the anti-CCP2-negative subset. Adjusting for reactivity against arginine-
containing control peptides did not uniformly change the diagnostic performance for antibodies against the
individual citrullinated peptides.
Conclusions: The multiplexed array, for detection of autoantibodies against multiple citrullinated epitopes on
candidate RA autoantigens, will be of benefit in studies of RA pathogenesis, diagnosis, and potentially as a guide
to individualized treatment.
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Introduction
With the discovery of anti-citrullinated protein/peptide
antibodies (ACPAs), the interest in autoantibodies has
increased during the last decade, from both a diagnostic
and a prognostic RA-perspective. In the former American
College of Rheumatology (ACR) 1987 classification criteria
for rheumatoid arthritis (RA) [1], the presence of rheuma-
toid factor (RF) accounted for one of seven criteria, of
which four should be met for an RA diagnosis. With the
introduction of the new 2010 RA classification criteria [2],
the impact of autoantibody serology has accordingly
increased, and can now contribute to half of the points
needed to classify a patient as having RA.
Commercial ACPA tests generally aim to identify col-
lectively as many antibodies against citrullinated epitopes
as possible. However, on the peptide level, the ACPA
response in RA patients has been shown to be heteroge-
neous, as different RA patients show reactivity against
different citrullinated peptides [3-8]. Although some stu-
dies have investigated the impact of having simultaneous
ACPA reactivity to different citrullinated peptides (see,
for example, [6-10]), such studies have hitherto been per-
formed with multiple parallel enzyme-linked immunosor-
bent assay (ELISA) tests, an approach that is laborious
and can demand sizeable volumes of scarce serum sam-
ples (for example, from historical cohorts). Such studies
of multiple detailed ACPA specificities have proven
informative concerning both the risk for RA development
in the context of risk genes [8,11], and the development
of risk of arthritis in healthy individuals [6] as well as in
arthralgia patients [7].
Most studies on ACPA fine specificity have so far
focused on individual antibody responses to epitopes on
three citrullinated autoantigens identified in rheumatoid
joints: fibrin/fibrinogen [12,13], vimentin [14], and a-eno-
lase [15,16], as well as the skin protein filaggrin, which was
used in the early RA-specific tests, before the discovery of
the nature of the ACPA response [17,18]. A smaller num-
ber of studies have also investigated the response to epi-
topes on the cartilage-specific type II collagen (CII),
another protein that has been found to be citrullinated in
RA joints [19]. This protein poses certain demands on the
assay used, as the native, noncitrullinated, triple-helical CII
molecule in itself is an autoantigen (anti-collagen II anti-
bodies AC2A), with conformational epitopes that differ
from the epitopes in the citrullinated counterpart [20].
The murine counterparts of both ACPA and AC2A to the
same epitopes have been crystallized and found to be dis-
tinct [20,21]. Practical limitations have probably limited
the number of ACPA epitopes investigated in parallel in
these earlier specificity studies.
Most commercial ACPA tests investigate only the
reactivity against citrullinated antigens, and only very
few tests take into account the possibility of reactivity
against the protein/peptide backbone by simultaneous
investigation of reactivity against the arginine-containing
noncitrullinated counterpart. Although the ACPA
response in RA has been shown to be citrulline specific,
a number of studies have shown false ACPA reactivity
with concomitant reactivity to arginine-containing con-
trol antigens in inflammatory diseases like pulmonary
tuberculosis [22,23], hepatitis C infection with cryoglo-
bulinemia [24], and autoimmune hepatitis [25]. During
our work with establishment of different ACPA ELISAs,
we also found that certain peptide backbones yield
increased ELISA reactivity, irrespective of whether the
peptide is investigated in its citrullinated or in its native
arginine-containing form. Altogether, these findings
argue for the usefulness of including arginine-containing
control antigens when investigating multiple citrulli-
nated antigens or unknown patient groups. Although
such control wells are normally excluded from commer-
cial ELISAs, to increase cost efficiency, they can easily
be added to miniaturized systems in a microarrayed
fashion. This was recently done in a microarray, allow-
ing the simultaneous evaluation of up to 10 antigens per
chip [26].
In this article, we describe the first version of a new
microarrayed platform allowing the simultaneous investi-
gation of more than 100 specific antibodies. In the pre-
sent form, the platform is used for investigation of the
ACPA response against 11 previously described citrulli-
nated peptides and their arginine-containing equivalents,
as well as one novel peptide, found to be citrullinated in
RA synovial membrane and not described before. The
peptides represent epitopes from five human autoanti-
gens (fibrinogen, a-enolase, vimentin, collagen type II,
and filaggrin), including multiple epitopes from the four
antigens (fibrinogen, a-enolase, vimentin, and collagen
type II) that have been found to be citrullinated in RA
joints. We show that the heterogeneous ACPA response
can be investigated with this technique in a serum-saving
way. We foresee that this assay can be used in studies on
RA patients in both prognostic and diagnostic contexts.
Materials and methods
Subjects
For this study, 984 RA patients and 472 healthy controls
from the Epidemiological Investigations in Rheumatoid
Arthritis (EIRA) case-control study were investigated.
EIRA cases have newly diagnosed (within 12 months of
first symptoms) RA according to the 1987 ACR classifica-
tion criteria [1], according to a rheumatologist, and were
aged 18 to 70 years at the time of inclusion. As the blood
samples were obtained at the first visit to a rheumatolo-
gist, no cases were treated with DMARDs or biologics,
whereas some cases were treated with NSAIDs and/or
low-dose (< 7.5 mg/day) prednisolone. Controls were
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randomly selected from the Swedish population registry,
with matching for sex, age, and residential area. As 57
RA patients and 11 controls showed nonspecific binding
in the microarray that rendered their corresponding
assay results somewhat uncertain (see later), these sam-
ples were excluded from analysis, and the final set
included 927 RA patients and 461 healthy controls.
Among the 927 RA patients, 401 (43.3%) were positive in
the anti-CCP2 ELISA assay (> 25 arbitrary units (AUs)/
ml; Immunoscan RA, Eurodiagnostica, Malmö, Sweden),
and the remaining RA patients were anti-CCP2 negative.
The EIRA samples selected for this methodologic investi-
gation were thus somewhat biased toward ACPA-nega-
tive samples, as compared with the entire EIRA study
[27].
Serum samples were drawn at the time of inclusion in
the EIRA study and thereafter stored frozen at -70°C.
All patients and controls had given written informed
consent before participating in the study, which had
been ethically approved by the regional ethics commit-
tee at Karolinska Institutet.
Citrullinated peptide microarray
Serum samples were analyzed for the presence of ACPA-
specific IgG by using a custom-made microarray, based
on the ImmunoCAP ISAC system (Phadia Multiplexing
Diagnostics GmbH, Vienna, Austria), containing 12 dif-
ferent citrullinated peptides and their native arginine-
containing counterparts. All peptides except Fibb60-74,
Fiba621-635, CCP-1/Fil307-324, and citC1 were obtained
at ≥ 95% purity from Innovagen AB (Lund, Sweden). The
CCP-1/Fil307-324 peptide was obtained from the same
source at 80% purity. The triple helical citC1 peptide was
synthesized as described in [28], analyzed with mass
spectrometry, Western blots and crystallographic analy-
sis, and checked by ELISA by using specific monoclonal
antibodies detecting either triple helical or denatured
forms of the peptide [21]. Peptides Fibb60-74, Fiba621-
635, and the corresponding arginine control peptides
were obtained from NeoMPS (Strasbourg, France) with a
purity of > 80%. All antigens were spotted in triplicate on
conventional microscopy glass slides with Teflon-masked
reaction fields (Marienfeld GmbH, Marienfeld, Germany)
coated with an amine-reactive polymer. The investigated
ACPAs are detailed in Table 1. The analyses were per-
formed according to the ImmunoCAP ISAC standard
assay procedure [29,30], with some deviations. In brief,
samples were diluted 1:40 in dilution buffer (Phadia), and
25 μl was added to the reaction wells of the microarray.
After a 2-hour incubation at room temperature in a
humidity chamber, the slides were washed, and 25 μl of
the secondary antibody, Cy3 conjugated goat anti-human
IgG (Jackson ImmunoResearch Laboratories Inc., New-
market, UK), was added to the reaction sites at a
concentration of 1 μg/ml. The slides were incubated for
30 minutes and then washed again before they were
scanned by using a laser scanner (LuxScan 10K; Capital-
Bio, Beijing, China). Fluorescence intensities were
recorded, and data processing was performed by using
the Microarray Image Analysis software (Phadia). This
software calculates intensity homogeneity as a coefficient
of variation (CV%) within individual spots, and intraspot
CV% within triplicate spots coated with the same peptide.
Both these CV% values must be < 25; otherwise, aberrant
spots are excluded. At least two spots in a triplicate must
be accepted to obtain results.
Validation against ELISAs for the individual citrullinated
peptides
The performance of the microarray was investigated by
comparison with individual ELISAs for the 12 included
citrullinated peptides. For each peptide, suitable serum
samples (between 40 and 100 samples per peptide)
encompassing a broad range of specific reactivities
against the individual citrullinated peptide were defined
by specific ELISAs, whereupon the same samples were
investigated with the microarray. ELISAs for 10 of the
peptides were performed at the Department of Rheuma-
tology, Karolinska Institutet, as described in [5]. Eight
ELISAs used individual standard curves produced by
serum samples with high levels of ACPA of the relevant
specificity, and ACPA levels were expressed as arbitrary
units (AUs) per milliliter. No corrections for reactivity
against arginine control peptides were done in ELISA or
microarray data for the corresponding eight peptides. For
four of the peptides (Fibb60-74, Fiba621-635, Fibb62-
81a, and Fibb62-81b), ELISA results were expressed as
optical densities (ODs) after subtraction of the OD for
the corresponding arginine-containing peptides, and
comparisons were done with the corresponding arginine-
subtracted fluorescence intensities from the microarray.
ELISAs for the peptides Fibb60-74 and Fiba621-635
were performed in the laboratory of Professor Guy Serre
in Toulouse, according to [31].
Statistics
Analyses were performed in two ways for each separate
citrullinated peptide. In a first investigation, gross data
for the results for the 12 citrullinated peptides in the 927
RA patients and 461 healthy controls were compared. In
the second evaluation, net ACPA results were calculated
by subtracting the fluorescence intensity for the arginine-
containing control peptide from each citrullinated pep-
tide for all RA patients and controls, whereupon these
net values were used to construct ROC curves and to
compare performance. This calculation of net ACPA
reactivity was performed for all peptides, except for citCI,
for which only uncorrected values were used, as the
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argC1 peptide is an autoantigen in its own right, and with
conformational epitopes differing from the citC1 peptide
[20,21].
To allow stringent comparison between performances
for the different citrullinated peptides, the cut-off point
for each investigation was defined as the fluorescence
intensity corresponding to a diagnostic specificity of
98.0%, calculated from the fluorescence intensities of the
investigations for the 461 healthy controls.
ACPA responses are known to show a bimodal distri-
bution clearly separating ACPA-positive and ACPA-
negative subjects, and studies on the correlation between
microarray and ELISA results were therefore performed
with the nonparametric Spearman Rank Test.
Receiver operator characteristic (ROC) curves were
constructed by using the Analyze-it software (Analyze-it
Software Ltd, Leeds, UK), and correlation between
ELISA and microarray results was calculated by using
the JMP software (SAS Inc., Cary, NC, USA).
Results
Performance of the ACPA microarray
When the laser-scanned slides were processed with the
Microarray Image Analysis software, the sites where the
citrullinated peptides had been spotted in triplicate were
clearly visualized after treatment with serum positive for
the corresponding autoantibodies. Examples of a positive
RA serum and a negative control serum are shown in
Figure 1.
Comparison of the fluorescence intensities in response
units (RUs) with corresponding ELISA units yielded
satisfactory correlations between the two techniques,
with Spearman r values typically between 0.75 and 0.90.
Three representative examples are shown in Figure 2a
through c.
The inter- and intraassay coefficient of variation (CV%)
was investigated by using serum samples with high
(15,000 to 60,000 RU), intermediate (1,500 to 15,000
RU), and low (50 to 1,500 RU) levels of antigen-specific
antibodies targeting representative citrullinated peptides
and their arginine-containing counterparts. The inter-
and intraassay CV% for samples with high levels of speci-
fic antibodies ranged from 8.3 to 16.8 and 5.3 to 17.0,
respectively. For the intermediate samples, the CV% was
9.5 to 22.8 and 10.3 to 19.3, respectively. The corre-
sponding figures for low-level samples were 5.0 to 22 and
13.3 to 31.4.
Besides the difference in reactivity between RA
patients (especially the anti-CCP2-positive patients) and
the healthy controls, a difference also was found in the
size of signals against the individual peptide backbones
that was common to both citrullinated peptides and to
arginine-containing control peptides, as well as to both
RA patients and controls. This fact manifested itself in
different cut-off values for the individual peptides: with
the highest values for Fibb580-600 (3,454 RU) and
Vim60-75 (2,500 RU) and the lowest for Vim2-17 (256
RU) and Fibb36-52 (222 RU). Peptides with generally
high fluorescence intensities in the microarray also
showed generally high OD levels in the parallel ELISA
investigations (data not shown).
Staining of the slides with some serum samples yielded
a fluorescence signal also from the glass surface sur-
rounding the triplicate areas with spotted antigen. This
happened in 57 (5.1%) of 984 of the RA sera and in 11
(2.3%) 472 of the control sera. As this phenomenon of
Table 1 Citrullinated peptides in the ACPA microarray
Peptide Protein Amino acids Amino acid sequence Reference
CEP-1/Eno5-21 a-Enolase 5-21 CKIHA(cit)EIFDS(cit)GNPTVEC (cyclic) [16]
Vim60-75 Vimentin 60-75 VYAT(cit)SSAV(cit)L(cit)SSVP [37]
Vim2-17 Vimentin 2-17 ST(cit)SVSSSSY(cit)(cit)MFGG [33]
CCP-1/Fil307-324 Filaggrin 307-324 SHQEST(cit)GRSRGRSGRSGS (cyclic) [3,32]
Fibb36-52 Fibrinogen b-chain 36-52 NEEGFFSA(cit)GHRPLDKK [37]
Fibb563-583 Fibrinogen b-chain 563-583 HHPGIAEFPS(cit)GKSSSYSKQF [13]
Fibb580-600 Fibrinogen b-chain 580-600 SKQFTSSTSYN(cit)GDSTFESKS c
Fibb62-81aa Fibrinogen b-chain 62-81 APPPISGGGY(cit)ARPAKAAAT [13]
Fibb62-81bb Fibrinogen b-chain 62-81 APPPISGGGYRA(cit)PAKAAAT [13]
Fibb60-74 Fibrinogen b-chain 60-74 (cit)PAPPPISGGGY(cit)A(cit) [12,31]
Fiba621-635 Fibrinogen a-chain 621-635 (cit)GHAKS(cit)PV(cit)GIHTS [12,31]
citC1/CII359-369 Collagen type II 359-369 (GPO)5-GA(cit)GLTG(cit)PGDA(GPO)2-GKKYG [20,28]
The arginine-containing control peptides have identical sequences, except that they contain arginine residues instead of citrulline (Cit, citrulline). Peptides are
designated by their abbreviated protein names (Eno, a-enolase; Vim, vimentin; Fib, fibrinogen; CII, type II collagen) followed by the positions of the first and last
amino acid. For three peptides, earlier given specific names (CEP-1, CCP-1, citC1), these names are given in parallel. aCitrullinated at position 72. Uses the same
control peptide containing two arginines as for Fibb62-81b. bCitrullinated at position 74. Uses the same control peptide containing two arginines as for Fibb62-
81a. cThe citrullinated epitope in this peptide has been found to be citrullinated in RA synovial tissue (Per-Johan Jakobsson, personal communication).
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Figure 1 Graphic representation of the fluorescence intensities obtained from (a) an ACPA-positive RA serum and (b) an ACPA-
negative control serum. Magnifications are shown to the right. The upper red frame shows reactivity to Fibb60-74, and the lower yellow frame
shows reactivity to CEP1/Eno5-21. Within each frame, the left triplicate shows reactivity to the citrullinated peptide, whereas the right triplicate
shows the reactivity to the native arginine-containing counterpart. Duplicate spots in the corners of both chips represent non-antigen-
dependent fluorescence used for technical alignment of the chips.
Figure 2 Correlation between measurements with ELISA and microarray for (a) Eno5-21, (b) Vim60-75, and (c) Fibb60-74. In a and b,
comparisons were made for uncorrected values, and in c, net values were determined after correction for reactivities against the arginine-
containing control peptide.
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nonspecific binding might conceal weakly reactive spots,
we decided to exclude samples with this reactivity pattern
from our further analyses. Exclusion of samples with
unspecific binding had, however, very limited effect on
the performance at group level and on the appearance of
ROC curves for the individual citrullinated peptides (data
not shown).
Discriminatory properties of individual citrullinated
peptides
When ROC curves were constructed for the individual
citrullinated peptides, they generally showed a high spe-
cificity pattern, with alignment with the Y axis, as is also
seen for anti-CCP2 [32]. Three examples of peptide
ROC curves are shown in Figure 3a through c. Notably,
substantial differences were noted in the frequency of
patients with positive reactivity for the different citrulli-
nated peptides. When the cut-off was set to exclude
98% of the healthy controls for each peptide, the micro-
array defined between 10.5% (Fibb580-600) and 45.2%
(Fibb36-52) of the RA patients in the selected EIRA
cohort as ACPA positive (Table 2).
Effects of the subtraction of arginine control reactivities
In parallel to evaluating the diagnostic properties of the
crude fluorescence intensities against the citrullinated
peptides, we also performed the same evaluation after
the fluorescence intensities for the control peptides con-
taining arginine had been subtracted for all samples
from RA patients and controls. In some cases, this cor-
rection increased the number of RA cases that were
positive in the assay (positive reaction defined as values
above the threshold set by the 98% negative reaction
rates among healthy controls): for reactivity against
Vim60-75, the number of positive patients increased
from 31.9% to 40.0%, and for Fiba621-635, a corre-
sponding increase was found from 26.9% to 29.0%. For
some peptides, subtraction of the arginine control values
instead decreased the number of positive sera: for Vim2-
17, from 10.8% to 8.0%, and for Fibb36-52, from 45.2%
Figure 3 Receiver operating characteristic (ROC) curves for (a) Eno5-21, (b) Vim60-75, and (c) Fibb60-74. The analyses were based on
comparisons between 927 RA patients (43.3% anti-CCP2 positive) and 461 healthy controls. AUC, Area under the curve.
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to 41.9%. For the other investigated peptides, the corre-
sponding differences were smaller, and of the 11 pep-
tides investigated, five showed increased, and six showed
decreased frequencies of positive reactions among the
RA patients after arginine correction. The performance
data for all investigated citrullinated peptides are shown
in Table 2.
Number of peptide reactivities in CCP2-positive and
CCP2-negative RA patients
Among the 927 investigated RA patients, the median
number of citrullinated peptide reactivities against the
12 investigated peptides was 2, and the mean, 3.33.
When the patients were split according to anti-CCP2
status, a marked difference between the groups was evi-
dent, as the corresponding figures were 7.0 and 6.48 for
the anti-CCP2-positive patients and 0.0 and 0.93 for the
anti-CCP2-negative patients. The median number of
positive reactions among the healthy controls was 0.0
(mean, 0.26). The distributions of the number of positive
ACPA reactions in the different groups are graphically
shown in Figure 4a through d.
Discussion
In this report, we describe a microarray in which specific
reactivities against multiple citrullinated peptides can be
investigated in parallel. Notwithstanding the microarray
approach, each one of the individual autoantibody reac-
tivities showed good correlation to results obtained with
parallel ELISAs for the individual peptides. With a large
validation cohort of RA patients and controls, followed
by ROC curve analyses, we could show that the indivi-
dual analyses showed high diagnostic specificity. At a
defined specificity level (98%), the individual peptides
showed marked differences in diagnostic performance,
with some individual peptides performing similarly to the
anti-CCP2 assay.
When the RA patients were split into those positive
and negative for anti-CCP2, a large difference was shown
in the number of peptide reactivities detected in the two
groups. This difference was particularly pronounced con-
cerning individuals with multiple reactivities. However, a
few patients also in the anti-CCP2-negative group
showed multiple reactivities against the citrullinated pep-
tides in the multiplex assay. This indicates that the
microarray might be useful for analyses of residual ACPA
reactivities that are not covered by the conventional
ACPA tests like anti-CCP2. The value of this assay to
generate hypotheses in a diagnostic setting remains to be
evaluated by using larger sets of sera from different
cohorts of RA patients and disease controls (patients
with infections and other noninfectious inflammatory
diseases). Of special interest will be the use of the assay
to estimate the risk of RA development in patients with
Table 2 Performance of the 12 investigated citrullinated peptides
Peptide Percentage of RA sera
reacting with the
individual citrullinated








Percentage of RA sera
reacting with the individual













Eno5-21 (CEP-1) 39.4 91.0 40.9 94.5 +
Vim60-75 31.9 73.7 40.0 92.4 +
Vim2-17 10.8 24.9 8.0 18.5 -
Fil307-324
(CCP1)
32.8 75.8 32.5 75.1 -
Fibb36-52 45.2 104.4 41.9 96.8 -
Fibb563-583 31.0 71.6 31.5 72.7 +
Fibb580-600 10.5 24.2 9.8 22.6 -
Fibb62-81a 19.8 45.7 20.6 47.6 +
Fibb62-81b 28.0 64.7 26.1 60.3 -
Fibb60-74 38.8 89.6 37.3 86.1 -
Fiba621-635 25.9 59.8 29.0 67.0 +
CII 359-369
(CitC1)
18.8 43.4 NDc NDc NDc
Peptides names are designated as in Table 1.
aThese percentages should be compared with the fact that 43.3% of all RA patients in the present selection of EIRA patients were anti-CCP2 positive.
bFluorescence intensities for the arginine control peptides were subtracted from the fluorescence intensities for each measurement among RA patients and
controls, whereupon the performance was calculated on the net values.
cNo subtraction was done for this peptide as the arginine control peptide is itself an autoantigen with conformational epitopes that are destroyed by
citrullination [20].
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early undifferentiated arthritis [6] and in other indivi-
duals at risk for RA. In such future studies, it will also be
possible to evaluate further the eventual diagnostic value
of the individual peptides included in the present multi-
plex assay.
In the current design, the microarray uses very small
quantities of serum (< 10 μl). This is an advantage when
available serum volumes are small and when replacement
samples are not available (for example, when samples
have been retrieved from historic biobanks, containing
samples taken from individuals at a time point before the
development of RA). We are currently performing such
studies on the development of individual ACPA
responses in sera from RA patients retrieved from his-
toric biobanks from the years preceding the development
of RA. In such studies, an imperative demand exists to
use small serum quantities very efficiently.
Certain sera yielded high background reactivities that
might obscure the readout for the individual antigens.
However, this is not unique to this specific microarray. It
is well known, among developers of addressable laser
bead immunoassays (ALBIA) and ELISA assays, that cer-
tain sera show unspecific binding. Given the setup of
most commercial ELISAs, in which each serum is investi-
gated only in wells coated with the antigen in question
but without serum-specific control wells, this unspecific
binding will often pass unperceived. Because we can
readily assess the overall nonspecific binding in the used
assay, we have excluded sera with apparent unspecific
binding, but have also noticed that inclusion of such sera
had very little effect on the performance at group level of
the citrullinated peptides used in this investigation.
We defined the cutoff levels as the 98th percentile for the
healthy controls, implying that 2% of the healthy controls
showed a positive response to each individual peptide. The
discriminatory property of each individual citrullinated
peptide in this multiplex assay is thus consistent with that
of the anti-CCP2 assay when comparing RA patients and
Figure 4 Histograms showing the relative frequency of subjects as a function of number of peptide reactivities against the 12
investigated citrullinated peptides for (a) all RA patients, (b) CCP-positive RA patients, (c) CCP-negative RA patients, and (d) healthy
controls.
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healthy controls. For stochastic reasons, this results in a
higher number of healthy controls having a positive signal
for any of the 12 analyzed peptides. These positive signals
were, however, mostly only slightly above the threshold,
and in only a very few of the healthy controls was multiple
reactivity seen, as was the case in most anti-CCP2-positive
RA patients.
Our initial pilot studies indicated a gain in diagnostic
sensitivity when subtracting the fluorescence intensities
from the arginine control peptides. However, in this vali-
dation, by using a large set of RA patients and controls,
this was not a universal finding, and similar numbers of
peptides showed decrease or increase in diagnostic per-
formance after correction for reactivity to control pep-
tides. We conclude that the issue of arginine subtraction
still is an open question, and that the most-suitable
approach has to be decided for each antigen/peptide.
This is also reflected by the different approaches used in
currently available commercial ACPA tests, in which
some assays, like the anti-Sa assay from Euroimmun,
include sample-specific control wells with noncitrulli-
nated antigen, whereas most assays, like the anti-CCP2
test, do not.
In a recent study by Chandra et al. [26], another multi-
plex approach was described for the detection of ACPAs,
by using a chip design with up to 10 antigens per chip.
Contrary to our study, biotinylated peptides were used
consistently by Chandra et al., and a different setup of
peptides was investigated. Thus, several features differ
between the two multiplex approaches, in which our
method may have certain advantages in allowing more
antigens to be investigated in parallel (up to 170 per
chip). However, a straight head-to-head comparison of
the two approaches to multiplexing will be needed to
harmonize the interpretation of ACPA multiplex
assaying.
As in our present investigation, the authors of the pre-
vious report [26] used no standard curve for normalization
of the responses against citrullinated peptides. Given the
many different reactivities that are investigated simulta-
neously, the construction of such a standard is a complex
task, and its resolution is not included in the present first
methods description of the current platform. However,
this issue also addresses future development of our multi-
plex platform.
A particular issue in any effort to measure antibodies
against several different epitopes on citrullinated autoan-
tigens is the degree of cross-reactivity between these dif-
ferent epitopes. Previous ELISA-based investigations
have addressed this issue by peptide-absorption experi-
ments and concluded that a large fraction of the anti-
bodies against epitopes included in our assay are not
cross-reactive, whereas a smaller fraction of antibodies
cross-react between different epitopes [7,8,33]. A further
complication is that half of the peptides used in the pre-
sent study, as well as the seven citrullinated peptides
described in the study by Chandra et al. [26], have mul-
tiple citrullination sites. As shown in Table 2 with the
98% specificity described for anti-CCP2 [32], reactivities
against several of the multicitrullinated peptides show a
similar degree of positivity as the anti-CCP2 assay does
in the same patient group, suggesting the presence of
multiple antibody-binding sites. Thus, we cannot rule
out the possibility that ACPAs with different fine speci-
ficities bind to different epitopes on these particular
peptides [31]. Further detailed studies using additional
peptides and different absorption approaches as done,
for example, in [8], will be needed to resolve these
issues.
RA subgroups with different clinical prognosis are
characterized by different autoantibody profiles. Besides
the ACPA (and RF)-associated RA phenotype associated
with poor long-term prognosis, we have, for example,
defined an acute-onset RA phenotype associated with
high levels of antibodies against native human CII
[34,35], whereas others have described a mild RA phe-
notype associated with antibodies against the RA33 anti-
gen [36]. Our aim is to use the microarray for the
simultaneous investigation of such autoantibody-defined
RA phenotypes in parallel.
Our long-term aim for the currently described multi-
plex assay platform is further to expand the number of
peptides and protein fragments included, and further to
validate the current and future antibody targets in addi-
tional clinical cohorts. Such extensions of numbers of
targets will be feasible, as abundant positions are left for
antigen spotting.
Conclusions
We have developed a microarray for the simultaneous
measurement of multiple specific ACPA responses. The
individual analytes have been quantitatively validated
against specific ELISAs and show a high specificity com-
parable to that of the anti-CCP2 assay. We foresee that
this assay will have a broad range of applications in stu-
dies of prediction, diagnosis, and prognosis of arthritis,
as well as in studies of specific ACPA responses before
and during conventional and experimental therapies in
RA.
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